CERVICAL SCREENING ANGELIKA KAUFMANN, ST4, UHCW, MEDICAL STUDENT INDUCTION, 2015
OUTLINE Cervical cancer HPV Screening in general Cervical screening The cervix Smear results Colopscopy
CERVICAL CANCER new cases world wide/year 80% in the developing world 2800 cervical cancer cases in the UK/ year Cervical screening saves approximately lives a year in England
RISK FACTORS FOR CERVICAL CANCER HPV infection (99%) Persistent HPV infection High viral load Smoking (increases risk x2) Multiple sexual partners Immunosuppression (HIV) Low socio-economic status prolonged use of oral contraceptive pill number of pregnancies (higher number of pregnancies = higher risk).
HPV (HUMAN PAPILLOMA VIRUS) Over 100 HPV subtypes Low risk:6+ 11, causing anogenital warts + respiratory papillomatosis High risk: (31, 33): oncogenic, causing: Cervical cancer Anal cancer Oral cancer Endemic, 95% of sexually active women will have HPV at some point in their life Majority of women will gain immunity and fight off HPV
HPV VACCINATION VLPs= “ virus like particles” (don’t contain DNA, non-infective) UK: start of immunisation in yrs yrs old girls + catch up thereafter Cervarix (bivalent) – HVP Switched to Gardasil in 2012: quadrivalent 3 doses over 6 months (0/2/6 months) Herd immunity Long-term studies ? Need for booster
WHO CRITERIA FOR SCREENING The condition sought should be an important health problem for the individual and community There should be an accepted treatment or useful intervention for patients with the disease The natural history of the disease should be adequately understood There should be a latent or early symptomatic stage There should be a suitable and acceptable screening test or examination Facilities for diagnosis and treatment should be available There should be an agreed policy on whom to treat as patients Treatment started at an early stage should be of more benefit than treatment started later The cost should be economically balanced in relation to possible expenditure on medical care as a whole Case finding should be a continuing process and not a once and for all project
CERVICAL SCREENING IN THE UK Organised way Failsafe mechanisms to ensure abnormal results are acted upon Standards and Quality control of The screener The laboratories Cyto- and Histopathologist Colposcopists
LIQUID BASED CYTOLOGY LBC used in the UK since Oct % unsatisfactory smears
NHS CERVICAL SCREENING PROGRAMME (NHSCSP) Liquid based cytology (LBC) Since 2003 (England) Age 25-50: every 3 years Age 51-65: every 5 years Scotland + Wales: Smears before the age of 25 could lead to unnecessary increased cervical treatment with potential negative consequences for future child bearing Sensitivity 70% 10% false negative smears
CERVICAL SCREENING PROGRAMME 2 Disabled women Women of ethnic minorities: communication/ leaflets/ information Lesbian/ bisexual women advised to be screened (“low risk, but not no risk”) Post hysterectomy Women with sub-total hysterectomy still require cervical screening Indication of hysterectomy: ie FU required for persistent CIN (vault smears)
CERVIX Ectocervix: multiple layers non-keratinizing stratified SQUAMOUS epithelium Endocervix: single layer COLUMNAR epithelium Transformation zone = area where columnar epithelium has undergone metaplasia to become squamous epithelium. Between the new and original squamo-columnar junction (Type 1/2/3).
TRANSFORMATION ZONE-COLPOSCOPIC VIEW External os Glandular epithelium/ectropion On ectocervix in Puberty Pregnancy Few weeks post natal (baby girl) New squamo-columnar junction Original squamo-columnar junction TRANSFORMATION ZONE
SMEAR TEST RESULTS DYSKARIOSIS is a cytological diagnosis: increased nuclear:cytoplasmic ratio mitotic figures nuclear pleomorphism nuclear hyperchromasia HPV features koilocytosis (vacuolated cells) hyperkeratosis multinucleation
SMEAR TEST RESULTS Normal Borderline change (with high risk HP) In squamous or endocervical cells Low grade dyskariosis High grade dyskariosis (moderate) High grade dyskariosis (Severe) ?glandular neoplasia of endocervical type ?Glandular neoplasia (non-cervical) Invasive disease Refer to colposcopy
TESTING FOR HPV Cytology and HPV, currently being implemented If high risk HPV positive, refer to colposcopy. HPV as test of cure HPV as primary test as precursor of cytology(currently being evaluated)
COLPOSCOPY Chaperone/ nurse Communication!! Ascitic acid (3%) Iodine Colposcope
COLPOSCOPY IMAGES Normal cervix CIN Punctations Mosacicism Normal cervix Iodine negative
CIN (CERVICAL INTRAEPTHELIAL NEOPLASIA) = histological diagnosis CIN 1 – bottom 1/3 abnormal CIN 2- bottom 2/3 abnormal CIN 3- full thickness abnormality CIN2 CIN3 CIN 1CIN 2CIN 3 Regress57%43%32% Persist32%35%56% Progress11%22% Invasive carcinoma 1%5%>12%
TREATMENT OF CIN CIN1 low malignant potential will usually resolve spontaneously encourage woman to quit smoking if persistent may be treated (excision/ablation) CIN 2/3 higher malignant potential standard treatment is excisional biopsy offer 'see-and-treat' treatment Treatment: excisional (ie LLETZ: large loop excision of transformation zone)
COLPOSCOPY IN PREGNANCY Defer routine screening (12 weeks postpartum). Difficult examination, only to be done by experienced colposcopist. Oedematous cervix Increased vascularity Ectropion (hyperoestrogenism) Aim: to exclude invasive disease. Biopsy only to exclude invasive lesions. If known smear abnormalities, arrange postpartum follow-up (3–4 months post delivery).
CASE 26 year old woman, first smear, referred with high grade-dyskariosis How would you explain the smear test result? What would you like to do next? How do you explain the examination/ treatment?